AMSbiopharma

Advanced Analytical CRO: where your needs find solutions

We provide analytical services to support the pharmaceutical, biopharmaceutical, and chemical industries at every stage of drug development

Services

R&D and Preclinical

Advanced analytical support for drug research and preclinical development

Quality control

Comprehensive services to ensure the highest standards
of quality and safety

Do you want to speak with a quality control scientist?

About us

Your trusted analytical CRO, partnering with industry leaders to offer tailored solutions and close communication. AMSbiopharma is the alternative for pre-clinical and quality control services, offering accuracy and reliability at every step

News

ICH Q8 guideline for pharmaceutical development: analytical strategies for quality by design in complex drug modalities

Regulatory expectations for pharmaceutical development have evolved considerably over the past two decades, from a compliance-driven and empirical...

Peptide purification in drug development: methods, techniques, and analytical strategies

The growing pipeline of peptide-based therapeutics has placed peptide purification at the center of pharmaceutical manufacturing strategy. From...

Metabolomics and lipidomics in drug discovery and development: analytical approaches for biomarker discovery and preclinical research

The search for safer, more effective medicines increasingly depends on understanding how biological systems respond to disease, genetic...

Drug development timeline: how early characterization prevents regulatory delays

The modern drug development timeline is highly shaped by manufacturing readiness, analytical understanding, and regulatory alignment. While innovation...

Chemistry, Manufacturing, and Controls (CMC) in the drug development process: analytical strategies to support Investigational New Drug (IND) readiness and regulatory progression

The transition from discovery to clinical evaluation represents one of the most critical inflection points in the drug...

Analytical strategies for gene and cell therapy products: From characterization to regulatory expectations

The rapid expansion of advanced therapies has transformed how medicines are designed, manufactured, and evaluated. Unlike traditional pharmaceuticals,...

EMA’s updated nitrosamines guideline: Implications for acceptable intake limits and analytical strategies

The landscape of impurity control in pharmaceutical manufacturing has been profoundly reshaped by the emergence of N-nitrosamines as...

Designing “fit-for-purpose” quality control protocols for biologics and nucleic acid therapeutics

The rapid maturation of nucleic acid therapeutics and complex biologics has necessitated a significant shift in the pharmaceutical...